The cyclic AMP phenotype of fragile X and autism

Neuroscience and Biobehavioral Reviews

Volumn 32, Issue 8, 2008, Pages 1533-1543

  Kelley, Daniel J ^a,b   Bhattacharyya, Anita ^a   Lahvis, Garet P ^b   Yin, Jerry C P ^c   Malter, Jim ^c   Davidson, Richard J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Autism; cAMP; Cyclic AMP; FMR1; FMRP; Fragile X; Signal transduction

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; CAFFEINE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIAZEPAM; FORSKOLIN; FRAGILE X MENTAL RETARDATION PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HT 0712; LITHIUM; MEM 1018; MEM 1091; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE C; ROLIPRAM; SECRETIN; UNCLASSIFIED DRUG; VALPROIC ACID;

AMYGDALOID NUCLEUS; AUTISM; CLINICAL FEATURE; COMORBIDITY; DROSOPHILA MELANOGASTER; DRUG EFFECT; FEEDBACK SYSTEM; FRAGILE X SYNDROME; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MEMORY; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANQUILIZING ACTIVITY; VOMITING;

ANIMALS; ANXIETY; AUTISTIC DISORDER; CYCLIC AMP; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MEMORY; MODELS, BIOLOGICAL; PHENOTYPE;

EID: 52049110500     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2008.06.005     Document Type: Review

References (214)

1. Ahloulay M., Dechaux M., et al. Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J. Clin. Invest. 98 10 (1996) 2251-2258
2. Aramori I., and Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron 8 4 (1992) 757-765
3. Araque A., Parpura V., et al. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22 5 (1999) 208-215
4. Arnetz B.B.H., Paul Stjaerne, Lennart Levi, and Lennart. Emotional stress increases plasma cyclic AMP in unrestrained rats. Reports from the Laboratory for Clinical Stress Research 99 (1979) 1-6
5. Azad S.C., Monory K., et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J. Neurosci. 24 44 (2004) 9953-9961
6. Bacchelli E., Blasi F., et al. Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene. Mol. Psychiatry 8 11 (2003) 916-924
7. Bach M.E., Barad M., et al. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 96 9 (1999) 5280-5285
8. Bakker C.E., Verheij C., et al. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian fragile X consortium. Cell 78 1 (1994) 23-33
9. Balazs R., Miller S., et al. Metabotropic glutamate receptor agonists potentiate cyclic AMP formation induced by forskolin or beta-adrenergic receptor activation in cerebral cortical astrocytes in culture. J. Neurochem. 70 6 (1998) 2446-2458
10. Barad M., Bourtchouladze R., et al. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U.S.A. 95 25 (1998) 15020-15025
11. Bear M.F., Huber K.M., et al. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27 7 (2004) 370-377
12. Beavo J.A., and Brunton L.L. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3 9 (2002) 710-718
13. Beazely M.A., and Watts V.J. Galpha(q)-coupled receptor signaling enhances adenylate cyclase type 6 activation. Biochem. Pharmacol. 70 1 (2005) 113-120
14. Beer B., Chasin M., et al. Cyclic adenosine monophosphate phosphodiesterase in brain: effect on anxiety. Science 176 4033 (1972) 428-430
15. Bernabeu R., Bevilaqua L., et al. Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats. Proc. Natl. Acad. Sci. U.S.A. 94 13 (1997) 7041-7046
16. Bernardet M., and Crusio W.E. Fmr1 KO mice as a possible model of autistic features. The Scientific World Journal 6 (2006) 1164-1176
17. Berry-Kravis E. Abnormal cyclic AMP production in tissues from individuals with fragile X syndrome. 1992 International Fragile X Conference proceedings (1992)
18. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev. Med. Child Neurol. 44 11 (2002) 724-728
19. Berry-Kravis E., and Ciurlionis R. Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells. J. Neurosci. Res. 51 1 (1998) 41-48
20. Berry-Kravis E., Hicar M., et al. Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. Pediatr. Res. 38 5 (1995) 638-643
21. Berry-Kravis E., and Huttenlocher P.R. Cyclic AMP metabolism in fragile X syndrome. Ann. Neurol. 31 1 (1992) 22-26
22. Berry-Kravis E., Krause S.E., et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J. Child Adolesc. Psychopharmacol. 16 5 (2006) 525-540
23. Berry-Kravis E., and Potanos K. Psychopharmacology in fragile X syndrome-present and future. Ment. Retard. Dev. Disabil. Res. Rev. 10 1 (2004) 42-48
24. Berry-Kravis E., and Sklena P. Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. Am. J. Med. Genet. 45 1 (1993) 81-87
25. Berry-Kravis E.H.P. Cyclic AMP metabolism in fragile X syndrome. Ann. Neurol. 28 (1990) 440
26. Bhattacharyya A., McMillan E., et al. Normal neurogenesis but abnormal gene expression in human fragile X cortical progenitor cells. Stem. Cells Dev. (2008)
27. Bian H., Zhang J., et al. Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem. Pharmacol. 68 11 (2004) 2229-2236
28. Bontekoe C.J.M., Bakker C.E., et al. Instability of a (CGG)98 repeat in the Fmr1 promoter. Hum. Mol. Genet. 10 16 (2001) 1693-1699
29. Bourtchouladze R., Lidge R., et al. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. PNAS 100 18 (2003) 10518-10522
30. Brennan F.X., Albeck D.S., et al. Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. Genes Brain Behav. 5 6 (2006) 467-471
31. Brouwer J.R., Mientjes E.J., et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated fragile X full mutation. Exp. Cell Res. 313 2 (2007) 244-253
32. Brown W.T., Friedman E., et al. Association of fragile X syndrome with autism. Lancet 1 8263 (1982) 100
33. Brown W.T., Jenkins E.C., et al. Fragile X and autism: a multicenter survey. Am. J. Med. Genet. 23 1-2 (1986) 341-352
34. Brown W.T., Jenkins E.C., et al. Autism is associated with the fragile-X syndrome. J. Autism Dev. Disord. 12 3 (1982) 303-308
35. Cabrera-Vera T.M., Vanhauwe J., et al. Insights into G protein structure, function, and regulation. Endocr. Rev. 24 6 (2003) 765-781
36. Camacho A., and Dimsdale J.E. Platelets and psychiatry: lessons learned from old and new studies. Psychosom. Med. 62 3 (2000) 326-336
37. Cartmell J., Schaffhauser H., et al. mGluR-evoked augmentation of receptor-mediated cyclic AMP formation in neonatal and adult rat striatum. Br. J. Pharmacol. 121 7 (1997) 1263-1268
38. Chavez-Noriega L.E., and Stevens C.F. Modulation of synaptic efficacy in field CA1 of the rat hippocampus by forskolin. Brain Res. 574 1-2 (1992) 85-92
39. Chen G., Hasanat K.A., et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom. Med. 61 5 (1999) 599-617
40. Chern Y. Regulation of adenylyl cyclase in the central nervous system. Cell Signal. 12 4 (2000) 195-204
41. Cherry J.A., and Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 407 2 (1999) 287-301
42. Cherry J.A., Thompson B.E., et al. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochimica Et Biophysica Acta-Gene Structure and Expression 1518 1-2 (2001) 27-35
43. Childers S.R. Opiate-inhibited adenylate cyclase in rat brain membranes depleted of Gs-stimulated adenylate cyclase. J. Neurochem. 50 2 (1988) 543-553
44. Childers S.R., Nijssen P., et al. Opiate-inhibited adenylate cyclase in mammalian brain membranes. NIDA Res. Monogr. 71 (1986) 65-80
45. Cohen I.L. A theoretical analysis of the role of hyperarousal in the learning and behavior of fragile X males. Mental Retardation & Developmental Disabilities Research Reviews 1 4 (1995) 286-291
46. Comery T.A., Harris J.B., et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad. Sci. U.S.A. 94 10 (1997) 5401-5404
47. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid. Res. Mol. Biol. 63 (1999) 1-38
48. Conti M., Richter W., et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 278 8 (2003) 5493-5496
49. Cook E.H. Autism: review of neurochemical investigation. Synapse 6 3 (1990) 292-308
50. Cornish K.M., Munir F., et al. Differential impact of the FMR-1 full mutation on memory and attention functioning: a neuropsychological perspective. J. Cogn. Neurosci. 13 1 (2001) 144-150
51. Cumbay M.G., and Watts V.J. Novel regulatory properties of human type 9 adenylate cyclase. J. Pharmacol. Exp. Ther. 310 1 (2004) 108-115
52. 2+/calmodulin-dependent pathway. Biochem. Pharmacol. 69 8 (2005) 1247-1256
53. DaSilva J.N., Lourenco C.M., et al. Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur. J. Nucl. Med. Mol. Imag. 29 12 (2002) 1680-1683
54. Davidson R.J. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol. Psychiatry 51 1 (2002) 68-80
55. Davidson R.J., Kalin N.H., et al. Lateralized effects of diazepam on frontal brain electrical asymmetries in rhesus monkeys. Biol. Psychiatry 32 5 (1992) 438-451
56. Davidson R.J., Kalin N.H., et al. Lateralized response to diazepam predicts temperamental style in rhesus monkeys. Behav. Neurosci. 107 6 (1993) 1106-1110
57. D'Sa C., Tolbert L.M., et al. Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J. Neurochem. 81 4 (2002) 745-757
58. Egorova L.K., Stepanichev M.Y., et al. Analysis of cyclic adenosine-3′,5′-monophosphate levels in structures of the informational and motivational systems of the rat brain during acquisition of a conditioned active avoidance reaction. Neurosci. Behav. Physiol. 33 4 (2003) 329-333
59. Elchaar G.M., Maisch N.M., et al. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann. Pharmacother. 40 6 (2006) 1086-1095
60. Entezam A., Biacsi R., et al. Regional FMRP deficits and large repeat expansions into the full mutation range in a new fragile X premutation mouse model. Gene 395 1-2 (2007) 125-134
61. Esch B.E., and Carr J.E. Secretin as a treatment for autism: a review of the evidence. Journal of Autism & Developmental Disorders 34 5 (2004) 543-556
62. Esteban J.A. AMPA receptor trafficking: a road map for synaptic plasticity. Mol. Interv. 3 7 (2003) 375-385
63. Ethell I.M., Irie F., et al. EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron 31 6 (2001) 1001-1013
64. Feldman H.M., Kolmen B.K., et al. Naltrexone and communication skills in young children with autism. J. Am. Acad. Child Adolesc. Psychiatry 38 5 (1999) 587-593
65. Ferguson J.N., Young L.J., et al. Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 25 3 (2000) 284-288
66. File S., and Hyde J. Can social interaction be used to measure anxiety?. Br. J. Pharmacol. 62 1978 (1978) 19-24
67. File S.E., and Seth P. A review of 25 years of the social interaction test. European Journal of Pharmacology 463 1-3 (2003) 35-53
68. Fleischhacker W.W., Hinterhuber H., et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26 1-2 (1992) 59-64
69. Florendo N.T., Barrnett R.J., et al. Cyclic 3′,5′-nucleotide phosphodiesterase: cytochemical localization in cerebral cortex. Science 173 998 (1971) 745-747
70. Francesconi A., and Duvoisin R.M. Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation. J. Biol. Chem. 273 10 (1998) 5615-5624
71. Francis S.H., Turko I.V., et al. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65 (2001) 1-52
72. Frey U., Huang Y.Y., et al. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260 5114 (1993) 1661-1664
73. Fu Y.H., Kuhl D.P., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67 6 (1991) 1047-1058
74. Fujita M., Zoghbi S.S., et al. Quantification of brain phosphodiesterase 4 in rat with (R)-[(11)C]Rolipram-PET. Neuroimage 26 4 (2005) 1201-1210
75. Gabellini N., Manev R.M., et al. Carboxyl domain of glutamate receptor directs its coupling to metabolic pathways. Neuroreport 4 5 (1993) 531-534
76. Gillott A., and Standen P.J. Levels of anxiety and sources of stress in adults with autism. J. Intellect. Disabil. 11 4 (2007) 359-370
77. Gilman A.G. Nobel lecture. G proteins and regulation of adenylyl cyclase. Biosci. Rep. 15 2 (1995) 65-97
78. Goldberg M. Plasma cyclic AMP and cyclic GMP in childhood-onset psychoses. Journal of Autism & Developmental Disorders 14 2 (1984) 159-164
79. Grabczyk E., and Usdin K. Generation of microgram quantities of trinucleotide repeat tracts of defined length, interspersion pattern, and orientation. Anal. Biochem. 267 1 (1999) 241-243
80. Greco C.M., Hagerman R.J., et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 125 8 (2002) 1760-1771
81. Greicius M.D., Boyett-Anderson J.M., et al. Reduced basal forebrain and hippocampal activation during memory encoding in girls with fragile X syndrome. Neuroreport 15 10 (2004) 1579-1583
82. Hagerman, R.J., 2002. The physical and behavioral phenotype. In: Hagerman, R.J., Hagerman, P.J. (Eds.), Fragile X Syndrome: Diagnosis, Treatment, and Research. The Johns Hopkins University Press, pp. 3-87.
83. Henkemeyer M., and Frisen J. Eph receptors tingle the spine. Neuron 31 6 (2001) 876-877
84. Hessl D., Rivera S.M., et al. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 10 1 (2004) 17-24
85. Higuchi H., Yang H.Y., et al. Rat neuropeptide Y precursor gene expression. mRNA structure, tissue distribution, and regulation by glucocorticoids, cyclic AMP, and phorbol ester. J. Biol. Chem. 263 13 (1988) 6288-6295
86. Horvath K., Stefanatos G., et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Phys. 9 1 (1998) 9-15
87. Hoshino Y., Kumashiro H., et al. Serum serotonin, free tryptophan and plasma cyclic AMP levels in autistic children-with special reference to their relation to hyperkinesia. Fukushima J. Med. Sci. 26 3-4 (1979) 79-91
88. Hoshino Y., Kumashiro H., et al. Plasma cyclic AMP level in psychiatric diseases of childhood. Folia Psychiatr. Neurol. Jpn. 34 1 (1980) 9-16
89. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid. Res. Mol. Biol. 69 (2001) 249-315
90. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370 Pt 1 (2003) 1-18
91. Huhman K.L., Hebert M.A., et al. Plasma cyclic AMP increases in hamsters following exposure to a graded footshock stressor. Psychoneuroendocrinology 16 6 (1991) 559-563
92. Hwu W.L., Wang T.R., et al. FMR1 enhancer is regulated by cAMP through a cAMP-responsive element. DNA Cell Biol. 16 4 (1997) 449-453
93. Ibrisimovic, E., Bilban, M., et al., 2007. Sensitization of cAMP formation in a neuron-like cell line. BMC Pharmacology 7 (Suppl 2) A18 (13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)).
94. Ingram J.L., Peckham S.M., et al. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22 3 (2000) 319-324
95. Insel P.A., and Ostrom R.S. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol. Neurobiol. 23 3 (2003) 305-314
96. Irie F., and Yamaguchi Y. EPHB receptor signaling in dendritic spine development. Front Biosci. 9 (2004) 1365-1373
97. Iwamoto M., Ishii F., et al. A physiological-response (plasma cyclic-Amp) and a psychological response (Stai-a-State) to noise exposure and/or calculation task. Journal of Sound and Vibration 186 4 (1995) 599-605
98. Ji, Y., Pang, P.T., et al., 2005. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. 8 (2), 164-172.
99. Kandel E.R., and Schwartz J.H. Molecular biology of learning: modulation of transmitter release. Science 218 4571 (1982) 433-443
100. Kaneko M., and Takahashi T. Presynaptic mechanism underlying cAMP-dependent synaptic potentiation. J. Neurosci. 24 22 (2004) 5202-5208
101. Kant G.J., Meyerhoff J.L., et al. Cyclic-Amp and cyclic-Gmp response to stress in brain and pituitary-stress elevates pituitary cyclic-Amp. Pharmacology Biochemistry and Behavior 17 5 (1982) 1067-1072
102. Kaufmann W.E., Cohen S., et al. Molecular phenotype of fragile X syndrome: FMRP, FXRPs, and protein targets. Microsc. Res. Tech. 57 3 (2002) 135-144
103. Kaufmann W.E., and Reiss A.L. Molecular and cellular genetics of fragile X syndrome. Am. J. Med. Genet. 88 1 (1999) 11-24
104. Kelley A.E., Schiltz C.A., et al. Neural systems recruited by drug- and food-related cues: studies of gene activation in corticolimbic regions. Physiol. Behav. 86 1-2 (2005) 11-14
105. Kelley, D., Davidson, R.J., et al., 2006. The cyclic AMP cascade is altered in fragile X neural tissue. Society for Neuroscience. Atlanta, GA, Neuroscience Meeting Planner Online. Program Number 196.15/oo20.
106. Kelley D.J., Davidson R.J., et al. The cyclic AMP cascade is altered in the fragile X nervous system. PLoS ONE 2 9 (2007) e931
107. Kim Y.-T., and Wu C.-F. Reduced growth cone motility in cultured neurons from Drosophila memory mutants with a defective cAMP cascade. J. Neurosci. 16 18 (1996) 5593-5602
108. Kolmen B.K., Feldman H.M., et al. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J. Am. Acad. Child Adolesc. Psychiatry 34 2 (1995) 223-231
109. Koski G., and Klee W.A. Opiates inhibit adenylate cyclase by stimulating GTP hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 78 7 (1981) 4185-4189
110. Laggerbauer B., Ostareck D., et al. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 10 (2001) 329-338
111. Lahvis G.P., and Bradfield C.A. Ahr null alleles: distinctive or different?. Biochem. Pharmacol. 56 7 (1998) 781-787
112. Lauder J.M. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci. 16 6 (1993) 233-240
113. Lein E.S., Hawrylycz M.J., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 7124 (2007) 168-176
114. Li J., Pelletier M.R., et al. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol. Cell Neurosci. 19 2 (2002) 138-151
115. Li Z., Zhang Y., et al. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29 11 (2001) 2276-2283
116. Loesch D.Z., Bui Q.M., et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci. Biobehav. Rev. 31 3 (2007) 315-326
117. Lombroso P.J. Genetics of childhood disorders: XLVIII. Learning and memory. Part 1. Fragile X syndrome update. J. Am. Acad. Child Adolesc. Psychiatry 42 3 (2003) 372-375
118. Lu H.C., She W.C., et al. Adenylyl cyclase I regulates AMPA receptor trafficking during mouse cortical 'barrel' map development. Nat. Neurosci. 6 9 (2003) 939-947
119. Lynch M.A. Long-term potentiation and memory. Physiol. Rev. 84 1 (2004) 87-136
120. Ma, L., Zablow, L., et al., 1999. Cyclic AMP induces functional presynaptic boutons in hippocampal CA3-CA1 neuronal cultures. 2 (1), 24-30.
121. MacKenzie, S.J., Baillie, G.S., et al., 2002. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). 136 (3), 421-433.
122. Maier N., and Schneirla T.C. Mechanisms of conditioning. Psych. Rev. 49 (1942) 117-134
123. Manganiello, V., 2002. Short-term regulation of PDE4 activity. 136 (3), 339-340.
124. Matulef K., and Zagotta W.N. Cyclic nucleotide-gated ion channels. Annu. Rev. Cell Dev. Biol. 19 (2003) 23-44
125. McBride S.M., Choi C.H., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45 5 (2005) 753-764
126. McBride S.M.J., Giuliani G., et al. Mushroom body ablation impairs short-term memory and long-term memory of courtship conditioning in Drosophila melanogaster. Neuron 24 4 (1999) 967-977
127. Menon V., Kwon H., et al. Functional brain activation during cognition is related to FMR1 gene expression. Brain Res. 877 2 (2000) 367-370
128. Michel C.I., Kraft R., et al. Defective neuronal development in the mushroom bodies of Drosophila fragile X mental retardation 1 mutants. J. Neurosci. 24 25 (2004) 5798-5809
129. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 2 (2003) 83-244
130. Miller A.H., Vogt G.J., et al. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 27 6 (2002) 939-948
131. Miller L.J., McIntosh D.N., et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am. J. Med. Genet. 83 4 (1999) 268-279
132. Mineur Y.S., Huynh L.X., et al. Social behavior deficits in the Fmr1 mutant mouse. Behav. Brain Res. 168 1 (2006) 172-175
133. Miyashiro K., and Eberwine J. Fragile X syndrome: (what's) lost in translation?. Proc. Natl. Acad. Sci. U.S.A. 101 50 (2004) 17329-17330
134. Miyashiro K.Y., Beckel-Mitchener A., et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37 3 (2003) 417-431
135. Montezinho L.P., Mork A., et al. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors. Bipolar Disord. 9 3 (2007) 290-297
136. Moos Jr. M., and Goldberg N.D. Cyclic AMP opposes IP3-induced calcium release from permeabilized human platelets. Second Messengers Phosphoproteins 12 4 (1988) 163-170
137. Nakagawa S., Kim J.-E., et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 22 9 (2002) 3673-3682
138. Neves S.R., Ram P.T., et al. G protein pathways. Science 296 5573 (2002) 1636-1639
139. Nibuya M., Nestler E.J., et al. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16 7 (1996) 2365-2372
140. Nimchinsky E.A., Oberlander A.M., et al. Abnormal development of dendritic spines in FMR1 knock-out mice. J. Neurosci. 21 14 (2001) 5139-5146
141. Nishijima I., Yamagata T., et al. Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior. Hum. Mol. Genet. 15 21 (2006) 3241-3250
142. Oostra B.A., and Willemsen R. A fragile balance: FMR1 expression levels. Hum. Mol. Genet. 12 Suppl. 2 (2003) R249-R257
143. Otte A.P., van Run P., et al. Neural induction is mediated by cross-talk between the protein kinase C and cyclic AMP pathways. Cell 58 4 (1989) 641-648
144. Pace T.W., Hu F., et al. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 21 1 (2007) 9-19
145. Pacheco R., Ciruela F., et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J. Biol. Chem. 279 32 (2004) 33352-33358
146. Pan L., Zhang Y.Q., et al. The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr. Biol. 14 20 (2004) 1863-1870
147. Pandey S.C. Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. Trends Pharmacol. Sci. 24 9 (2003) 456-460
148. Panksepp J. A neurochemical theory of autism. Trends Neurosci. 2 (1979) 174-177
149. Panksepp J. Affective Neuroscience: The Foundations of Human and Animal Emotions (1998), Oxford University Press, New York
150. Panksepp J., Normansell L., et al. Effects of neonatal decortication on the social play of juvenile rats. Physiol. Behav. 56 3 (1994) 429-443
151. Panksepp J.B., and Lahvis G.P. Social reward among juvenile mice. Genes Brain Behav. 6 7 (2007) 661-671
152. Paradee W., Melikian H.E., et al. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94 1 (1999) 185-192
153. Parker C.A., Matthews J.C., et al. Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse 55 4 (2005) 270-279
154. Peier A.M., McIlwain K.L., et al. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum. Mol. Genet. 9 8 (2000) 1145-1159
155. Pieretti M., Zhang F.P., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66 4 (1991) 817-822
156. Pilc A., Legutko B., et al. The enhancement and the inhibition of noradrenaline-induced cyclic AMP accumulation in rat brain by stimulation of metabotropic glutamate receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 4 (1996) 673-690
157. Prather P., Tsai A., et al. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells. J. Pharmacol. Exp. Ther. 270 1 (1994) 177-184
158. Qin M., Kang J., et al. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J. Neurosci. 25 20 (2005) 5087-5095
159. Qin M., Kang J., et al. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U.S.A. 99 24 (2002) 15758-15763
160. Rao V.S., Santos F.A., et al. Effects of acute and repeated dose administration of caffeine and pentoxifylline on diazepam-induced mouse behavior in the hole-board test. Psychopharmacology (Berl.) 144 1 (1999) 61-66
161. Rapin I. Autism. N. Engl. J. Med. 337 2 (1997) 97-104
162. Reiss A.L., and Freund L. Fragile X syndrome. Biol. Psychiatry 27 2 (1990) 223-240
163. Reiss A.L., Lee J., et al. Neuroanatomy of fragile X syndrome: the temporal lobe. Neurology 44 7 (1994) 1317-1324
164. Restifo L.L. Mental retardation genes in drosophila: new approaches to understanding and treating developmental brain disorders. Ment. Retard. Dev. Disabil. Res. Rev. 11 4 (2005) 286-294
165. Rich T.C., Fagan K.A., et al. Cyclic nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted cAMP diffusion. J. Gen. Physiol. 116 2 (2000) 147-161
166. Riddle M.A., Bernstein G.A., et al. Anxiolytics, adrenergic agents, and naltrexone. J. Am. Acad. Child Adolesc. Psychiatry 38 5 (1999) 546-556
167. Rinaldi T., Silberberg G., et al. Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. Cereb. Cortex (2007)
168. Rius R.A., Mollner S., et al. Developmental changes in Gs and Golf proteins and adenylyl cyclases in mouse brain membranes. Brain Res. 643 1-2 (1994) 50-58
169. Rius R.A., Streaty R.A., et al. Developmental expression of G proteins that differentially modulate adenylyl cyclase activity in mouse brain. FEBS Lett. 288 1-2 (1991) 51-54
170. Robichaud A., Savoie C., et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 135 1 (2002) 113-118
171. Robichaud A., Stamatiou P.B., et al. Deletion of phosphodiesterase 4D in mice shortens {alpha}2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110 7 (2002) 1045-1052
172. Rodrigues S.M., Schafe G.E., et al. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron 44 1 (2004) 75-91
173. Schenck A., Van de Bor V., et al. Novel features of dFMR1, the Drosophila orthologue of the fragile X mental retardation protein. Neurobiol. Dis. 11 1 (2002) 53-63
174. Schmidt M.J., Palmer E.C., et al. Cyclic AMP and adenyl cyclase in the developing rat brain. Dev. Psychobiol. 3 1 (1970) 53-67
175. Schneirla, T.C., 1959. An evolutionary and developmental theory of biphasic processes underlying approach and withdrawal. In: Dienstbier, R. (Ed.), Nebraska Symposium on Motivation. University of Nebraska Press, Lincoln, pp. 1-42.
176. Seamon K.B., and Daly J.W. Forskolin: its biological and chemical properties. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20 (1986) 1-150
177. Seamon K.B., Padgett W., et al. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. U.S.A. 78 6 (1981) 3363-3367
178. Seed N., and Gilman A.G. Norepinephrine stimulated increase of cyclic AMP levels in developing mouse brain cell cultures. Science 174 4006 (1971) 292
179. Serajee F.J., Zhong H., et al. The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism. J. Med. Genet. 40 4 (2003) e42
180. Silvestre J.S., Fernandez A.G., et al. Effects of rolipram on the elevated plus-maze test in rats: a preliminary study. J. Psychopharmacol. 13 3 (1999) 274-277
181. Siu F.K., Lam I.P., et al. Signaling mechanisms of secretin receptor. Regul. Pept. 137 1-2 (2006) 95-104
182. Smith K.T., Nicholls R.D., et al. The gene encoding the fragile X RNA-binding protein is controlled by nuclear respiratory factor 2 and the CREB family of transcription factors. Nucleic Acids Res. 34 4 (2006) 1205-1215
183. Spencer C.M., Alekseyenko O., et al. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes, Brain and Behavior 4 7 (2005) 420-430
184. Stahl S.M. The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archives of General Psychiatry 34 5 (1977) 509-516
185. Stone E.A., and John S.M. Stress-induced increase of extracellular levels of cyclic AMP in rat cortex. Brain Res. 597 1 (1992) 144-147
186. Sturmey P. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res. Dev. Disabil. 26 1 (2005) 87-97
187. Sullivan K., Hooper S., et al. Behavioural equivalents of anxiety in children with fragile X syndrome: parent and teacher report. J. Intellect. Disabil. Res. 51 Pt 1 (2007) 54-65
188. Takahashi M., Terwilliger R., et al. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19 2 (1999) 610-618
189. Takuro Tojima S.K., and Etsuro Ito. Dual role of cyclic AMP-dependent protein kinase in neuritogenesis and synaptogenesis during neuronal differentiation. Journal of Neuroscience Research 74 6 (2003) 829-837
190. Tang W.J., and Hurley J.H. Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol. Pharmacol. 54 2 (1998) 231-240
191. Tateyama M., and Kubo Y. Dual signaling is differentially activated by different active states of the metabotropic glutamate receptor 1{alpha}. PNAS 103 4 (2006) 1124-1128
192. Taylor A.K., Tassone F., et al. Tissue heterogeneity of the FMR1 mutation in a high-functioning male with fragile X syndrome. Am. J. Med. Genet. 84 3 (1999) 233-239
193. Thomsen C. Metabotropic glutamate receptor subtype 1A activates adenylate cyclase when expressed in baby hamster kidney cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 4 (1996) 709-726
194. Tseng K.Y., and O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 24 22 (2004) 5131-5139
195. Tsiouris J.A., and Brown W.T. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs 18 11 (2004) 687-703
196. Verkerk A.J., Pieretti M., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65 5 (1991) 905-914
197. Volk L.J., Pfeiffer B.E., et al. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J. Neurosci. 27 43 (2007) 11624-11634
198. Wagner G.C., Reuhl K.R., et al. A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate. J. Autism Dev. Disord. 36 6 (2006) 779-793
199. Walton K.M., and Rehfuss R.P. Molecular mechanisms of cAMP-regulated gene expression. Mol. Neurobiol. 4 3-4 (1990) 197-210
200. Wang H., Ferguson G.D., et al. Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat. Neurosci. 7 6 (2004) 635-642
201. 2+- and protein kinase C-dependent pathway. J. Neurochem. 93 1 (2005) 232-245
202. Weiler I.J., Spangler C.C., et al. From the Cover: fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. PNAS 101 50 (2004) 17504-17509
203. Weisskopf M.G., Castillo P.E., et al. Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP. Science 265 5180 (1994) 1878-1882
204. Willemsen R., Hoogeveen-Westerveld M., et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum. Mol. Genet. 12 9 (2003) 949-959
205. Willemsen-Swinkels S.H., Buitelaar J.K., et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch. Gen. Psychiatry 52 9 (1995) 766-773
206. Williams D.L., Goldstein G., et al. The profile of memory function in children with autism. Neuropsychology 20 1 (2006) 21-29
207. Williams G., King J., et al. Fetal valproate syndrome and autism: additional evidence of an association. Developmental Medicine & Child Neurology 43 3 (2001) 202-206
208. Williams K.W., Wray J.J., et al. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst. Rev. 3 (2005) CD003495
209. Winsberg B.G., Sverd J., et al. Estimation of monoamine and cyclic-AMP turnover and amino acid concentrations of spinal fluid in autistic children. Neuropediatrics 11 3 (1980) 250-255
210. Wong S.T., Athos J., et al. Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP. Neuron 23 4 (1999) 787-798
211. Zhang H.T., Huang Y., et al. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl.) 179 3 (2005) 613-619
212. Zhang H.T., Zhao Y., et al. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29 8 (2004) 1432-1439
213. Zhao M.-G., Toyoda H., et al. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J. Neurosci. 25 32 (2005) 7385-7392
214. Zingarelli G., Ellman G., et al. Clinical effects of naltrexone on autistic behavior. Am. J. Ment. Retard. 97 1 (1992) 57-63